SCHEMBL24534758

SCHEMBL24534758

C/C=C1/N=C(c2ccc(Cl)cc2)OC1=O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.58
DAPK3 O43293 2/20 0.58
ALDH1A1 P00352 3/20 0.56
L3MBTL1 Q9Y468 2/20 0.56
POLB P06746 1/20 0.56
MAPT P10636 1/20 0.56
PKM P14618 1/20 0.56
RECQL P46063 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
ALOX5 P09917 1/20 0.53
NPC1 O15118 6/20 0.51
RAB9A P51151 6/20 0.51
SMN1; SMN2 Q16637 7/20 0.50
HPGD P15428 1/20 0.47
TP53 P04637 1/20 0.45
MAPK1 P28482 1/20 0.45
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
NOTUM Q6P988 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22505232 0.85 SMN1; SMN2 (0.64) GAADAPK3ALDH1A1L3MBTL1POLB
SCHEMBL24241399 0.85 NPC1 (0.69) GAADAPK3ALDH1A1L3MBTL1POLB
SCHEMBL21217197 0.84 SMN1; SMN2 (0.68) GAADAPK3ALDH1A1L3MBTL1POLB
SCHEMBL12914553 0.84 SMN1; SMN2 (0.68) GAADAPK3ALDH1A1L3MBTL1POLB
SCHEMBL24241482 0.84 NPC1 (0.49) GAADAPK3ALDH1A1L3MBTL1POLB
SCHEMBL24241458 0.83 NPC1 (0.61) GAADAPK3ALDH1A1L3MBTL1NPC1
SCHEMBL24534523 0.83 NPC1 (0.61) GAADAPK3ALDH1A1L3MBTL1NPC1
SCHEMBL17187167 0.83 RAB9A (0.76) GAADAPK3ALDH1A1L3MBTL1POLB
SCHEMBL17187168 0.83 RAB9A (0.76) GAADAPK3ALDH1A1L3MBTL1POLB
SCHEMBL22505100 0.81 CSNK2A2 (0.61) GAADAPK3ALDH1A1L3MBTL1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220193041-A1 NOVEL COMPOUND AND METHOD FOR PREVENTING OR TREATING OF RESPIRATORY DISEASES COMPRISING THE SAME AS AN ACTIVE INGREDIENT Yonsei University, University - Industry Foundation (UIF) (KR) 2022-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220193041-A1 NOVEL COMPOUND AND METHOD FOR PREVENTING OR TREATING OF RESPIRATORY DISEASES COMPRISING THE SAME AS AN ACTIVE INGREDIENT EPX, CFTR, MPO GAA 148/4885DAPK3 4191/4885ALDH1A1 1549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.